Abstract
Current advances in molecular techniques and bioinformatics allowed the analysis of complex molecular patterns in various cancers including muscle-invasive bladder cancer. As a consequence, in the last few years numerous gene- and protein expression-based molecular classifications have been recommended. Recently a comprehensive consensus classification for muscle-invasive urothelial bladder cancer has been published, distinguishing 6 subgroups with a potential impact on clinical decision-making. At the same time, the therapeutic landscape of muscle-invasive bladder cancer becomes increasingly differentiated as novel checkpoint inhibitors have been available for cisplatin-ineligible and/or resistant patients. Furthermore, promising results have been obtained with FGFR targeting agents. Therefore, molecular subtyping will probably have a crucial role in individualized therapeutic decision-making in bladder cancer. In the present work, we summarize the evolution, recent advances and potential therapeutic relevance of molecular subclassifications in bladder cancer. Orv Hetil. 2019; 160(42): 1647-1654.
Highlights
Molecular subtype classification of urothelial bladder cancer and its clinical relevance Current advances in molecular techniques and bioinformatics allowed the analysis of complex molecular patterns in various cancers including muscle-invasive bladder cancer
The therapeutic landscape of muscle-invasive bladder cancer becomes increasingly differentiated as novel checkpoint inhibitors have been available for cisplatin-ineligible and/or resistant patients
Promising results have been obtained with FGFR targeting agents
Summary
A húgyhólyag urothelialis daganatainak molekuláris alcsoportbeosztása és annak klinikai vonatkozásai. Továbbá ígéretes kezelési lehetőséget jelentenek az FGFR-támadáspontú szerek is. Jelen munkánkban összefoglalást nyújtunk az izominvazív húgyhólyagrák molekuláris alcsoportbeosztásáról, valamint annak klinikai jelentőségéről. Kulcsszavak: izominvazív húgyhólyagrák, molekuláris alcsoport, ciszplatinalapú kemoterápia, checkpointgátló, génexpressziós mintázat. A comprehensive consensus classification for muscle-invasive urothelial bladder cancer has been published, distinguishing 6 subgroups with a potential impact on clinical decision-making. Promising results have been obtained with FGFR targeting agents. Molecular subtyping will probably have a crucial role in individualized therapeutic decision-making in bladder cancer. We summarize the evolution, recent advances and potential therapeutic relevance of molecular subclassifications in bladder cancer. Szarvas T, Oláh Cs, Riesz P, Géczi L, Nyirády P. [Molecular subtype classification of urothelial bladder cancer and its clinical relevance].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
